Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist...
70 insider sale filings on record · latest filing 2026-09-25.
No open-market insider purchases (SEC Form 4 code P) on record for PHVS.